Companies › Tonix Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Other, Psychiatry; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cyclobenzaprine Hydrochloride (TNX-102) Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | Major Depressive Episode (MDE); Pharmakokinetic | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07413367 | Cyclobenzaprine Hydrochloride (TNX-102) | Phase 1 | Pharmakokinetic | Other | Feb 2026 |
| NCT07621237 | Cyclobenzaprine Hydrochloride (TNX-102) | Phase 2 | Major Depressive Episode (MDE) | Psychiatry | Feb 2028 |
Cash of $163m on 2026-09-30; operating cash outflow about $169m a year; runway about 12 months at that burn, to Sep 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Clear Scientific Syndeio Biosciences NeuroRx MapLight Therapeutics COMPASS Pathways
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.